In a simple study into the control of polio in the Third World a town was divided into 16 zones and pulses of oral polio vaccine given at one station in each zone, after extensive publicity about the campaign. Some 62% of children received three doses of the vaccine and the incidence of polio fell dramatically over the study period.
Introduction
Paralytic poliomyelitis is a major public health problem in many developing countries. In India alone over 500 children become paralysed each day because of polio. 
Vaccination programme
Vellore is a town of 174 000 (1981 census) inhabitants in Tamilnadu State in southern India. A local polio surveillance system was established in January 1980. All reported cases were seen by the study physician to confirm the clinical diagnosis, to collect faecal samples for virology, and to verify the place of residence of the child before the onset of the illness. Uninterrupted surveillance is continuing.
The town was divided into 16 zones and oral polio vaccine was administered at one station in each zone in a three-dose campaign at monthly intervals at the end of 1981. Publicity was given through slide presentation in cinemas, newspaper announcements, and the wide distribution of hand bills. Each campaign lasted four half-days with four stations operating simultaneously. Because this was the first year of pulse immunisation children from 0 to 4 years were eligible for vaccination. In February 1982 a 30-cluster sample survey was conducted to assess vaccination source and coverage, using a WHO recommended method.
Results
At the first pulse campaign in September 1981 only 2465 children were vaccinated, as the publicity hand bills had not been distributed. The campaign was rescheduled for October, November, and December, when 5592, 6298, and 6976 children respectively were vaccinated. Altogether 21 341 doses were given. In November measles vaccine was also given to children from 1 to 4 years.
In the cluster-sample survey 84% of 1 to 2-year-old children had received at least one dose of oral polio vaccine, 73% had received two doses, 620 three doses, 180% four doses, and 11 % five doses. Of all the doses accounted for, 40% had been given through the pulse campaign and 60% through hospitals or private practitioners over a long period.
In 1980 and 1981, 51 and 43 children respectively had clinically confirmed acute paralytic poliomyelitis reported through the surveillance system ( figure) . From the 1980-1 data, assuming they follow a Poisson distribution and ignoring seasonality, the fall in the number of cases was highly significant (p < 0001). During the first three quarters of 1982 no cases have been reported.
Comment
The reduction in the incidence of reported poliomyelitis was as gratifying as it was dramatic; 62% of children were given three doses of oral polio vaccine. In many developing countries polio has not been controlled by regular age-specific immunisation through fixed centres, even in towns with over 60% coverage with three doses. Control was achieved in this campaign as a result of the wild polioviruses in circulation being replaced by the widespread pulse of vaccine viruses.5 Pulse immunisation will increase the coverage rate as well as the seroconversion rate, presumably owing to the circulation of vaccine viruses.4 Thus some children who were missed in the pulse campaign may also become immunised. As a result the circulation of wild polioviruses would be interrupted and the incidence of poliomyelitis in the community would fall.4
This study shows that polio can be controlled in small geographical units. As more resources become available the area covered can be increased until the whole nation achieves control over polio.
Introduction
The past 20 years has seen an explosion in the introduction of effective cytotoxic agents for treating malignant disease (fig 1) . Not only has the number of agents increased, so has the frequency with which they are used.
Until relatively recently chemotherapy tended to be used only in specialised units on small numbers of patients with rare tumours. With the growth of chemotherapy as an adjuvant to surgery and radiotherapy, however, and with the advent of multicentre clinical trials in common malignancies, these drugs are now prescribed much more widely. This increased use may produce an unduly heavy burden on medical and pharmaceutical
